| |
著者: P Hau, D Koch, T Hundsberger, E Marg, B Bauer, R Rudolph, M Rauch, A Brenner, P Rieckmann, J Schuth, T Jauch, H Koch, U Bogdahn
雑誌名: Neurology. 2007 Feb 27;68(9):688-90. doi: 10.1212/01.wnl.0000255937.27012.ee.
Abstract/Text
We surveyed neuro-oncologists regarding patients treated with temozolomide for at least 12 cycles or 12 months. Patients receiving first-line temozolomide for a median 13 cycles had a median progression-free survival (PFS) of 14 months. Patients with recurrent disease receiving a median 14 cycles had a median PFS of 15.5 months. A small percentage of patients experienced grade III to IV toxicity. These results suggest that long-term treatment with temozolomide is feasible and well tolerated.
PMID 17325277 Neurology. 2007 Feb 27;68(9):688-90. doi: 10.1212/01.wnl.0000255937.27012.ee.
|
